Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2005
11/10/2005US20050250810 Screening for an enzyme inhibitor of Fab I or Fab K using providing a reaction mixture comprising Fab I or Fab K, crotonyl-ACP and NAPDH or NADH; contacting a candidate compound with the reaction mixture; and detecting inhibition of Fab I or Fab K; bactericides; fungicides; antibiotics; Stapylococcus
11/10/2005US20050250809 Reacting chloroperbenzoic acid with 3-dichloromethylthio-7-fluoro-1-,ethyl-4-quinolone in dichloromethane;
11/10/2005US20050250808 Each compound having an azabicyclic ring attached via a ring N or amino group; neuroprotectants; neurodegenerative diseases, analgesics, psychological disorders; e.g. 5-Methoxy-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1H-indazole-3-carboxamide; ligands for nicotinic acetylcholine receptors
11/10/2005US20050250807 Neurotrophin antagonist compositions
11/10/2005US20050250806 Nicotinic acetylcholine receptor antagonists in the treatment of restless legs syndrome
11/10/2005US20050250805 Pharmaceutical ointment formulations
11/10/2005US20050250804 Pharmaceutical gel formulations
11/10/2005US20050250803 Combination of dopamine agonists and monoamine reuptake inhibitors
11/10/2005US20050250802 Novel substituted amines of spirofuropyridines useful in therapy
11/10/2005US20050250801 Method of treating cancer with azaspirane compositions
11/10/2005US20050250800 Conformationally constrained compounds as pharmaceutical agents
11/10/2005US20050250799 Protease inhibitors for treatment of wrinkles
11/10/2005US20050250798 E.g., 8-{[(2S)-2-(Methoxymethyl)pyrrolidin-1-yl]sulfonyl}-3,4-dihydropyrimido[1,2-a]indol-10(2H)-one; caspase inhibitors used to treat diseases including arthritis, myocardial infarction or stroke
11/10/2005US20050250797 Quinzoline derivatives for use in the treatment of cancer
11/10/2005US20050250796 Suppress tumor necrosis factor; Crohn's disease; imflammatory bowel disorders; sepsis; autoimmune disease
11/10/2005US20050250795 Synthesis of the viricide valomaciclovir stearate in which an acyclic hydroxymethylbutyl acetal derivative is reduced to the alcohol, reacted with an activated amino acid and N-deprotected; one pot reactions; herpes and retroviral infections
11/10/2005US20050250794 Use of heterocyclic compounds such as thiophenes, 1,2,4-triazoles and benzoxazoles; as inhibitors of deacetylase SirT1 protein sirtuin to treat neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders such as diabetes
11/10/2005US20050250793 Preventives/remedies for hot flash
11/10/2005US20050250792 Substituted piperidine compounds useful as modulators of chemokine receptor activity
11/10/2005US20050250791 Process for preparing monoarylpiperazines
11/10/2005US20050250790 Novel sulfonic acid derivatives
11/10/2005US20050250789 Hydroxamic acid derivatives as metalloprotease inhibitors
11/10/2005US20050250788 Aqueous outflow enhancement with vasodilated aqueous cavity
11/10/2005US20050250787 Pyrimidine compounds
11/10/2005US20050250786 PNA monomer and precursor
11/10/2005US20050250785 PNA monomer and precursor
11/10/2005US20050250784 1-(2-naphthylsulfonyl)-4-(5-hydroxyaminocarbonylthiazol-2-yl)piperazine;antiprolifrative agent; cell cycle arrest, cellular differentiation, apoptosis and reversal of the transformed phenotype;
11/10/2005US20050250783 N-(2-Amino-6-phenyl-5,6,7,8-tetrahydro-quinazolin-6-ylmethyl)-2-methoxy-benzamide, used in the treatment of arrhythmia
11/10/2005US20050250782 Heterocyclic inhibitors of MEK and methods of use thereof
11/10/2005US20050250781 (1-piperidine-3-cyclopentane)-amide derivatives; antiinflammatory agent, antiallergen; autoimmune diseases; allergic rhinitis, dermatitis, conjunctivitis, asthma, rheumatoid arthritis and atherosclerosis
11/10/2005US20050250780 Piperimido[1,2-a]piperazine-4,7diones derivatives; neurokinin (tachykinin) receptor antagonists; mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins; analgesic, neurodegenerative disorders, respiratory diseases, antiinflammatory agent, antidepressant
11/10/2005US20050250779 Pteridinone derivatives for treating ocular hypertension
11/10/2005US20050250778 Topical brimonidine tartrate formulations that lack chlorine dioxide
11/10/2005US20050250777 Novel derivatives of cycloalcanodiones, method for the production thereof and their pharmacological applications
11/10/2005US20050250775 Novel compounds
11/10/2005US20050250774 N-{2-[2-(3,4-Dimethoxy-phenyl)-ethoxy]-6-morpholin-4-yl-pyridin-4-yl}-N'-(1 H-indol-3-ylmethylene)-hydrazine; interleukin IL-12 overproduction-related disorder; antiinflammatory agent; autoimmune diseases: multiple sclerosis, sepsis, neuropathies, cirrhosis, hepatitis, diabetes, arthritis
11/10/2005US20050250773 Reacting mycophenolic acid with C1 to C 4 alcohol or 4-(2-hydroxyethyl)morpholine in presence of catalyst; solvent-free; extraction; crystallization
11/10/2005US20050250772 Methods for inducing anti-anxiety and calming effects in animals and humans
11/10/2005US20050250771 Substituted indoles and their use as integrin antagonists
11/10/2005US20050250770 Fused heterocyclic compounds
11/10/2005US20050250769 5-Methyl-1-(tetrahydro-pyran-2-ylmethyl)-2-(4-trifluoromethoxy-phenyl)-1H-imidazole-4-carboxylic acid piperidin-1-ylamide; CB1 receptor modulation; obesity; antidiabetic agents;anxiolytic agents; psychosis; schizophrenia; antidepressants; drug abuse/dependance; multiple sclerosis; headaches; antieleptic
11/10/2005US20050250768 Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
11/10/2005US20050250767 Use of N-desmethylclozapine to treat human neuropsychiatric disease
11/10/2005US20050250766 Purification of progesterone receptor modulators
11/10/2005US20050250765 Diazepinones as antiviral agents
11/10/2005US20050250764 Solution of an HIV protease inhibitor in a combination of suitable pharmaceutical organic solvents, a surfactant and a bioavailability enhancer; suitable for the preparation of oral solutions for the administration of active drugs and for encapsulation in hard gelatin capsules or soft gelatin capsules
11/10/2005US20050250763 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
11/10/2005US20050250761 such as -Piperidin-1-yl-but-2-enoic acid [4(3-chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-yl]-amide, used as tyrosine kinase inhibitors, for the prevention of proliferative diseases, including cancer, atherosclerosis, restenosis, endometriosis and psoriasis
11/10/2005US20050250760 1-[(Indol-3-yl)carbonyl]piperazine derivatives
11/10/2005US20050250759 1-Azaspiro[3.5]nona-5,8-diene-2,7-dione derivatives 1-substituted with an oxy, thio, amino or carbonyl group, e.g., 1-Methoxy-1-azaspiro[3.5]nona-5,8-diene-2,7-dione; use as UV absorbers
11/10/2005US20050250758 Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use
11/10/2005US20050250757 Use of targeted oxidative therapeutic formulation in treatment of cancer
11/10/2005US20050250756 Use of targeted oxidative therapeutic formulation in treatment of age-related macular degeneration
11/10/2005US20050250755 administering to the patient an effective amount of a pharmaceutical formulation comprising:reaction products resulting from oxidation of menthol or an alkene such as geraniol by an oxygen-containing oxidizing agent; a penetrating solvent dimethylsulfoxide; a chelated dye; and an aromatic redox compound
11/10/2005US20050250753 hormone sensitive diseases such as prostate hypertrophia, benign prostatic hyperplasia, adenomas and neoplasies of the prostate, prostate cancer, hirsutism, and polycystic ovary syndrome; dibenz[b,f]azocine, dibenzo[b,f][1,4]thiazocine, dibenz[b,f][1,5]oxazocine derivatives; anticancer, antitumor agents
11/10/2005US20050250752 Cembranoids with chemopreventive activity
11/10/2005US20050250751 neo-tanshinlactone is excluded; treating cancer
11/10/2005US20050250750 Methods for treating postmenopausal women using ultra-low doses of estrogen
11/10/2005US20050250749 Helix 12 directed pharmaceutical products
11/10/2005US20050250748 Combination therapy of angiotensin converting enzyme inhibitor and eplerenone for treatment of cardiovascular disease
11/10/2005US20050250747 Management of breakthrough bleeding in extended hormonal contraceptive regimens
11/10/2005US20050250746 Premenstrual dysphoric disorder medication
11/10/2005US20050250745 Biomarkers for age-related macular degeneration (AMD)
11/10/2005US20050250744 Pharmaceutically active compounds and methods of use thereof
11/10/2005US20050250742 Phosphate/sulfate ester compounds and pharmaceutical composition for inhibiting protein interacting NIMA (PIN1)
11/10/2005US20050250741 non-steroidal agonists and antagonists; 2-(2-ethylsulfanyl-1-hydroxy-1-methyl-ethyl)-6-trifluoromethyl-1H-indole-5--carbonitrile; anticarcinogenic; prostate carcinoma, benign prostatic hyperplasia (BPH), hirsutism, alopecia, anorexia nervosa, breast cancer, acne, AIDS, cachexia, as a male contraceptive
11/10/2005US20050250740 Novel indole derivatives as selective androgen receptor modulator (SARMS)
11/10/2005US20050250739 for treating neurological diseases including Parkinson's and related diseases; Hydrophilic transportable N-linked glycosyl dopaminergic prodrug compounds
11/10/2005US20050250738 Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin
11/10/2005US20050250737 Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
11/10/2005US20050250736 Composition and method for treatment of obesity and smoking cessation
11/10/2005US20050250735 Modified pectins, compositions and methods related thereto
11/10/2005US20050250734 Compositions, kits, and methods for the treatment of conditions associated with elevated cholesterol levels
11/10/2005US20050250733 Purified, moderately esterified polyol polyester fatty acid compositions
11/10/2005US20050250732 Purified, moderately esterified polyol polyester fatty acid compositions
11/10/2005US20050250731 Synthesis of purified, moderately esterified polyol polyester fatty acid compositions
11/10/2005US20050250730 Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
11/10/2005US20050250729 Sulfonamido derivatives with a conserved ethyl uronamide group;1-deoxy-1-[6-[[[[4-[N-(benzyl)aminosulfonyl]phenyl]amino]-carbonyl]amino]-9H-purin-9-yl]-N-ethyl- beta -D-ribofuranuronamide or derivatives; anticarcinogenic, antiinflammatory, antiischemic, antiepileptic, and hypertensive agents
11/10/2005US20050250728 Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof
11/10/2005US20050250727 Use of immunomodulating agents
11/10/2005US20050250726 Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
11/10/2005US20050250723 Immunostimulation by chemically modified RNA
11/10/2005US20050250720 Novel compound
11/10/2005US20050250719 Inhibition of protein kinase c alpha for treatment of diabetes mellitus and cardiovascular diseases
11/10/2005US20050250716 Immunostimulatory oligodeoxynucleotides
11/10/2005US20050250715 Remedy
11/10/2005US20050250714 Crystalline forms of 9-(S)-erythromycylamine
11/10/2005US20050250713 11,12-Cyclic thiocarbamate macrolide antibacterial agents
11/10/2005US20050250712 Single dose azithromycin
11/10/2005US20050250710 Antiaging composition
11/10/2005US20050250709 Anti-neoplastic agents, combination therapies and related methods
11/10/2005US20050250708 Novel C-glycosides, uses thereof
11/10/2005US20050250707 HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
11/10/2005US20050250706 Processes for the preparation of alpha polymorph of perindopril erbumine
11/10/2005US20050250705 Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
11/10/2005US20050250704 Powder comprising new compositions of oligosaccharides and methods for their preparation
11/10/2005US20050250703 Antioxidant constituents
11/10/2005US20050250701 Method of treating the syndrome of coronary heart disease risk factors in humans
11/10/2005US20050250695 Combination PDGF, KGF, IGF, and IGFBP for wound healing
11/10/2005US20050250679 Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and methods of use
1 ... 4473 4474 4475 4476 4477 4478 4479 4480 4481 4482 4483 4484 4485 4486 4487 4488 4489 4490 4491 4492 4493 ... 7860